argenx
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease.
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- argenx
- Target Recruit Count
- 108
- Registration Number
- NCT06307626
- Locations
- 🇦🇹
Hanusch-Krankenhaus - Vienna Institute for Research in Ocular Surgery, Wien, Austria
🇧🇬AIPSMAED Sveti Luka EOOD, Plovdiv, Bulgaria
🇧🇬Multi-Profile Hospital for Active Treatment (MHAT) Hadji Dimitar, Sliven, Bulgaria
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 108
- Registration Number
- NCT06307613
- Locations
- 🇺🇸
Quest Diagnostics - Mercy Smith Glynn Callaway, Springfield, Missouri, United States
🇧🇬St. Petka Eye Hospital - Eye Clinic St. Petka Varna, Varna, Bulgaria
🇨🇳Fujian Medical University Union Hospital, Fuzhou, China
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 279
- Registration Number
- NCT06299748
- Locations
- 🇺🇸
United BioSource LLC, Morgantown, West Virginia, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- argenx
- Target Recruit Count
- 110
- Registration Number
- NCT06298552
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇨🇳Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chongqing, China
🇨🇳Guangdong Province Traditional Chinese Medical Hospital, Guangzhou, China
A Non-interventional, Post-authorisation Safety Study of Patients Treated with Efgartigimod Alfa
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- argenx
- Target Recruit Count
- 680
- Registration Number
- NCT06298565
- Locations
- 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸BayCare Health System, Inc. St Anthony's Hospital, St. Petersburg, Florida, United States
🇺🇸Prairie Education and Research Cooperative and HSHS Medical Group, O'Fallon, Illinois, United States
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults with Dermatomyositis
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- argenx
- Target Recruit Count
- 42
- Registration Number
- NCT06284954
- Locations
- 🇺🇸
Integral Rheumatology and Immunology Specialists (IRIS), Plantation, Florida, United States
🇺🇸Profound Research LLC, Oceanside, California, United States
🇺🇸Omega Research Debary, LLC, Debary, Florida, United States
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- argenx
- Target Recruit Count
- 24
- Registration Number
- NCT06203457
- Locations
- 🇵🇱
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k., Poznan, Poland
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
ðŸ‡ðŸ‡ºVita Verum Medical Egeszsegugyi Szolgaltato Bt., Szekesfehervar, Hungary
A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)
- Conditions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- argenx
- Target Recruit Count
- 30
- Registration Number
- NCT06078553
- Locations
- 🇨🇦
The Ottawa Hospital - Civic Campus, Ottawa, Canada
🇫🇷CHU Timone, Marseille, France
🇫🇷Assistance Publique Hopitaux de Paris - Hopital Pitie-Salpetriere, Paris, France
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
- Conditions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- argenx
- Target Recruit Count
- 150
- Registration Number
- NCT05988073
- Locations
- 🇺🇸
Stanford Medicine Health Care - Stanford Neuroscience Health Center, Palo Alto, California, United States
🇺🇸Oregon Health and Science University (OHSU) Hospital - Marquam Hill Campus, Portland, Oregon, United States
🇺🇸Penn Medicine - Penn Medicine University City, Philadelphia, Pennsylvania, United States
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- argenx
- Target Recruit Count
- 240
- Registration Number
- NCT05979441
- Locations
- 🇺🇸
Neuromuscular Clinical and Research Center - Neurology, Phoenix, Arizona, United States
🇺🇸Attune Health Research, Inc, Beverly Hills, California, United States
🇺🇸UCI Health - ALS and Neuromuscular Center - Neurology, Orange, California, United States